Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 26, 2023; 11(3): 528-533
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.528
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.528
Exosomal miRNA in early-stage hepatocellular carcinoma
Zhi-Qiang Wu, Yi-Xin Zhu, Yin-Chu Zhan, Department of Surgery, The Second People's Hosptal of Quzhou, Quzhou 324000, Zhejiang Province, China
Yun Jin, Department of Surgery, The Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310009, Zhejiang Province, China
Author contributions: Wu ZQ and Zhu YX designed and reviewed the manuscript; Wu ZQ, Zhu YX, and Jin Y wrote the paper; All authors read and approved the manuscript; Wu ZQ and Zhu YX contributed equally to this work.
Supported by the Quzhou Science and Technology Guided Project Planning , No. 2019133 .
Conflict-of-interest statement: We declare that we have no conflict of interest related to this work.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yin-Chu Zhan, MD, Director, Surgeon, Department of Surgery, The Second People's Hosptal of Quzhou, No. 338 Xin'an Avenue, Qujiang District, Quzhou 324000, Zhejiang Province, China. qzhospzyc@163.com
Received: October 28, 2022
Peer-review started: October 28, 2022
First decision: December 19, 2022
Revised: December 26, 2022
Accepted: January 5, 2023
Article in press: January 5, 2023
Published online: January 26, 2023
Processing time: 90 Days and 11.8 Hours
Peer-review started: October 28, 2022
First decision: December 19, 2022
Revised: December 26, 2022
Accepted: January 5, 2023
Article in press: January 5, 2023
Published online: January 26, 2023
Processing time: 90 Days and 11.8 Hours
Core Tip
Core Tip: The prognosis of hepatic carcinoma (HCC) is poor and surgical resection is the only potential radical cure. Early diagnosis of HCC is a key approach in improving clinical outcomes. However, the sensitivity and specificity of current early screening methods for HCC are not satisfactory. Exosomal miRNAs have become a candidate for early diagnosis and treatment of HCC. This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.